DENTSPLY SIRONA (NASDAQ:XRAY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

DENTSPLY SIRONA (NASDAQ:XRAY) posted its quarterly earnings results on Thursday. The medical instruments supplier reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.02), FiscalAI reports. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business had revenue of $836.00 million during the quarter, compared to analyst estimates of $861.68 million. During the same quarter in the prior year, the business earned $0.37 earnings per share. The firm’s quarterly revenue was down 7.5% on a year-over-year basis. DENTSPLY SIRONA updated its FY 2026 guidance to 1.200-1.300 EPS.

Here are the key takeaways from DENTSPLY SIRONA’s conference call:

• DENTSPLY SIRONA lowered its 2026 outlook: sales are now expected to be approximately $3.5 billion, and adjusted EPS $1.20–$1.30, down from prior ranges of $3.5–$3.6 billion and $1.40–$1.50, respectively.
• Q3 revenue fell 7% in constant currency to $836 million, and adjusted EPS declined to $0.29 from $0.42 a year ago. Dental businesses faced lower volumes, planned dealer inventory reductions, and pressure in EMEA.
• Operating cash flow decreased to $32 million from $79 million, primarily due to unfavorable working capital; net debt to EBITDA was 3.4, and management said debt reduction remains a priority.
• Q3 results included a $39 million pre-tax accounting benefit from refining estimates of intercompany profit in inventory transfers; management said it reflects multiple years, is not expected to recur, and is included in the updated EPS outlook.
• Management cited early growth areas, including record Wellspect sales, up 10%, double-digit U.S. growth in MIS implants, and a return to growth in U.S. endodontics. It is expanding sales coverage and clinical education, while cautioning that broader, sustained improvement is still needed.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $9.46 on Friday. The company has a market capitalization of $1.89 billion, a P/E ratio of 6.92, a P/E/G ratio of 1.27 and a beta of 0.87. DENTSPLY SIRONA has a 1-year low of $8.14 and a 1-year high of $14.76. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07. The firm’s 50 day simple moving average is $9.60 and its two-hundred day simple moving average is $11.28.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Growth at Wellspect provided some support amid weakness elsewhere in the business. XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut
• Negative Sentiment: Q3 adjusted earnings of $0.29 per share fell short of the $0.31 analyst consensus, while revenue of $836 million missed the roughly $862 million estimate. Revenue declined about 7.5% year over year, and EPS was lower than the $0.37 reported a year earlier. Third-quarter and nine-month results
• Negative Sentiment: The company cut its 2026 adjusted EPS guidance to $1.20–$1.30, below the $1.47 analyst consensus, and forecast revenue of $3.5 billion versus expectations of $3.6 billion. The lower outlook reinforces concerns about continued demand weakness. XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut

Wall Street Analyst Weigh In

XRAY has been the topic of several research analyst reports. Mizuho lowered their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, October 22nd. BMO Capital Markets decreased their target price on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating for the company in a research report on Thursday, September 17th. Bank of America reissued a “buy” rating on shares of DENTSPLY SIRONA in a research note on Friday. Leerink Partners reduced their price target on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating for the company in a report on Wednesday, October 14th. Finally, Barclays raised their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. Three investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.64.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.